Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:APLM NYSE:CPHI NASDAQ:ERNA NASDAQ:LSTA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPLMApollomics$13.83+0.9%$14.27$3.66▼$42.12$30.09M1.5310,241 shs15,864 shsCPHIChina Pharma$0.71-6.8%$0.70$0.38▼$2.05$28.96M1.16183,620 shs25,040 shsERNAErnexa Therapeutics$6.15-6.1%$7.48$3.18▼$71.50$7.65M2.49137,248 shs27,962 shsLSTALisata Therapeutics$3.56+2.3%$3.62$1.81▼$5.07$31.69M0.81219,056 shs56,329 shsThe 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPLMApollomics+3.15%+1.85%-0.50%-28.35%+109.08%CPHIChina Pharma+0.12%-9.14%-14.09%+28.67%-52.07%ERNAErnexa Therapeutics+3.31%-20.02%-45.46%-19.16%-88.98%LSTALisata Therapeutics-3.60%+3.26%+6.75%-30.82%+41.46%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPLMApollomics$13.83+0.9%$14.27$3.66▼$42.12$30.09M1.5310,241 shs15,864 shsCPHIChina Pharma$0.71-6.8%$0.70$0.38▼$2.05$28.96M1.16183,620 shs25,040 shsERNAErnexa Therapeutics$6.15-6.1%$7.48$3.18▼$71.50$7.65M2.49137,248 shs27,962 shsLSTALisata Therapeutics$3.56+2.3%$3.62$1.81▼$5.07$31.69M0.81219,056 shs56,329 shsThe 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPLMApollomics+3.15%+1.85%-0.50%-28.35%+109.08%CPHIChina Pharma+0.12%-9.14%-14.09%+28.67%-52.07%ERNAErnexa Therapeutics+3.31%-20.02%-45.46%-19.16%-88.98%LSTALisata Therapeutics-3.60%+3.26%+6.75%-30.82%+41.46%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPLMApollomics 1.00SellN/AN/ACPHIChina Pharma 0.00N/AN/AN/AERNAErnexa Therapeutics 2.00Hold$30.00387.80% UpsideLSTALisata Therapeutics 1.67Reduce$15.00321.35% UpsideCurrent Analyst Ratings BreakdownLatest ERNA, LSTA, APLM, and CPHI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/4/2026APLMApollomics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/18/2026LSTALisata Therapeutics Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold5/15/2026LSTALisata Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Neutral5/14/2026APLMApollomics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/11/2026ERNAErnexa Therapeutics Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold5/7/2026ERNAErnexa Therapeutics Brookline Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$30.004/21/2026ERNAErnexa Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/21/2026LSTALisata Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)3/27/2026APLMApollomics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)(Data available from 6/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPLMApollomics$8.50M3.58N/AN/A($2.89) per share-4.78CPHIChina Pharma$3.99M7.25N/AN/A$0.70 per share1.02ERNAErnexa Therapeutics$580K12.41N/AN/A$7.64 per share0.80LSTALisata Therapeutics$170K190.77N/AN/A$1.66 per share2.14Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPLMApollomics-$10.94MN/AN/AN/AN/AN/AN/AN/AN/ACPHIChina Pharma-$3.08M-$0.55N/AN/AN/A-85.56%-63.93%-31.42%N/AERNAErnexa Therapeutics-$14.08M-$26.20N/AN/AN/AN/A-263.74%-151.16%8/12/2026 (Estimated)LSTALisata Therapeutics-$16.59M-$1.86N/AN/AN/AN/A-103.54%-83.08%8/6/2026 (Estimated)Latest ERNA, LSTA, APLM, and CPHI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/20/2026Q1 2026ERNAErnexa Therapeutics-$1.95-$6.95-$5.00-$6.95N/AN/A5/11/2026Q1 2026ERNAErnexa Therapeutics-$1.95-$6.95-$5.00-$6.95N/AN/A5/11/2026Q1 2026LSTALisata TherapeuticsN/A-$0.50N/A-$0.50N/AN/A3/12/2026Q4 2025LSTALisata Therapeutics-$0.74-$0.33+$0.41-$0.33N/A$0.10 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAPLMApollomicsN/AN/AN/AN/AN/ACPHIChina PharmaN/AN/AN/AN/AN/AERNAErnexa TherapeuticsN/AN/AN/AN/AN/ALSTALisata TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPLMApollomicsN/A0.960.96CPHIChina Pharma0.220.790.26ERNAErnexa TherapeuticsN/A2.892.89LSTALisata TherapeuticsN/A4.234.23Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPLMApollomics19.13%CPHIChina PharmaN/AERNAErnexa Therapeutics70.55%LSTALisata Therapeutics8.94%Insider OwnershipCompanyInsider OwnershipAPLMApollomicsN/ACPHIChina Pharma6.40%ERNAErnexa Therapeutics0.53%LSTALisata Therapeutics9.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAPLMApollomics452.20 millionN/ANot OptionableCPHIChina Pharma25040.52 million15.92 millionNot OptionableERNAErnexa Therapeutics101.17 million1.16 millionNo DataLSTALisata Therapeutics309.11 million8.23 millionNot OptionableERNA, LSTA, APLM, and CPHI HeadlinesRecent News About These CompaniesLisata Therapeutics (NASDAQ:LSTA) Stock Price Up 4.3% - Here's WhyJune 11 at 2:21 AM | americanbankingnews.comLisata Therapeutics, Inc.: Lisata Therapeutics Announces Commencement of Tender Offer by Kuva Labs Inc.June 10 at 11:20 AM | finanznachrichten.deLisata Therapeutics agrees to Kuva Labs buyout at $4 per shareJune 10 at 9:38 AM | proactiveinvestors.comLisata Therapeutics Announces Tender Offer from Kuva Acquisition Corp at $4.00 per Share Plus Contingent Value RightsJune 10 at 8:30 AM | quiverquant.comQLisata Therapeutics Announces Commencement of Tender Offer by Kuva Labs Inc.June 10 at 8:00 AM | globenewswire.comKuva and Lisata Therapeutics Tender Offer UpdateJune 1, 2026 | tennessean.comTHC Wainwright & Co. downgrades Lisata Therapeutics (LSTA)May 16, 2026 | msn.comLisata Therapeutics Amends Kuva Labs Merger Agreement TimelineMay 9, 2026 | theglobeandmail.comHalper Sadeh LLC is Investigating Whether SILA and LSTA are Obtaining Fair Deals for their ShareholdersMay 4, 2026 | globenewswire.comLisata Therapeutics Delays Tender Offer Launch in MergerApril 3, 2026 | tipranks.comLeading Financial Trade Associations, Led by LSTA, Submit Amicus Brief in Support of Defendant Lenders in Antitrust Case Filed by Optumum CommunicationsMarch 26, 2026 | businesswire.comLisata Therapeutics shares up 20% as Kuva Labs acquisition advancesMarch 10, 2026 | finance.yahoo.comLisata Therapeutics to be acquired by Kuva LabsMarch 9, 2026 | proactiveinvestors.comShareholder Alert: The Ademi Firm investigates whether Lisata Therapeutics Inc. is obtaining a Fair Price for its Public ShareholdersMarch 9, 2026 | prnewswire.comLisata Therapeutics Enters into Definitive Agreement to be Acquired by Kuva Labs, Inc.March 6, 2026 | globenewswire.comLisata Extends Kuva Labs Acquisition Term Sheet TimelineFebruary 27, 2026 | tipranks.comLisata Therapeutics (LSTA) price target decreased by 26.92% to 9.69February 4, 2026 | msn.comLisata Therapeutics ends Qilu certepetide collaboration dealJanuary 27, 2026 | tipranks.comLisata regains China rights to pancreatic cancer drugJanuary 27, 2026 | proactiveinvestors.comLisata Therapeutics Announces Mutual Termination of License Agreement with Qilu Pharmaceutical for CertepetideJanuary 27, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSpaceX IPO: Opportunity? Or the Ultimate Hype Trade?By Chris Markoch | May 22, 2026Overextended, e.l.f. Beauty Is Primed to Rebound in Back HalfBy Thomas Hughes | May 22, 2026Japan's Stealth Bull Market: How U.S. Investors Can Get ExposureBy Chris Markoch | May 17, 2026YETI Rallies After Earnings Beat and Raised OutlookBy Jennifer Ryan Woods | May 14, 2026The Great Cloud Divide: How AI Is Reshuffling the Software DeckBy Jeffrey Neal Johnson | May 20, 2026ERNA, LSTA, APLM, and CPHI Company DescriptionsApollomics NASDAQ:APLM$13.83 +0.13 (+0.92%) Closing price 03:58 PM EasternExtended Trading$14.30 +0.48 (+3.46%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Apollomics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to eradicate cancer. The company's products portfolio includes Vebreltinib (APL-101), an oral active, highly selective c-Met inhibitor, which is in Phase 2 clinical trials for treatment of non-small cell lung cancer; APL-102, an oral active, small molecule Multiple Tyrosine Kinase Inhibitor, which is in a in a Phase 1 clinical trial to inhibit various kinases that are aberrantly activated in cancer cells; and APL-122, a tumor inhibitor candidate, targeting ErbB1/2/4 signaling pathwaysthat is in Phase 1 dose escalation clinical trials to treat cancers within the brain. Its also developing uproleselan (APL-106) that is in Phase 3 clinical trial for the treatment of adult patients with relapsed or refractory AML, as well as Phase 2/3 study with uproleselan for the treatment of newly diagnosed older adults with AML; and APL-108, a second-generation E-selective inhibitor, which has completed Phase 1 clinical trials to treat other liquid and solid cancers. The company's pipeline consists of preclinical stage immuno-oncology product candidates, such as APL-501, APL-502, APL-801 and APL-810. Its solutions include tumor inhibitors, anti-cancer enhancers, and immune-oncology drugs. Apollomics, Inc. was formerly known as CBT Pharmaceuticals, Inc. and changed its name to Apollomics, Inc. in January 2019. The company was incorporated in 2015 and is based in Foster City, California.China Pharma NYSE:CPHI$0.71 -0.05 (-6.82%) Closing price 04:00 PM EasternExtended Trading$0.76 +0.05 (+6.35%) As of 06:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.China Pharma Holdings, Inc. develops, manufactures, and markets generic and branded pharmaceutical, and biochemical products to hospitals and private retailers in the People's Republic of China. The company provides products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. Its products include Cerebroprotein Hydroloysate injection to treat memory decline and attention deficit; Gastrodin injection for tiredness, loss of concentration, poor sleep, and traumatic syndromes of the brain; Propylgallate injection to treat cerebral thrombosis, coronary heart disease, and after surgery complications; Ozagrel Sodium to treat acute thrombotic cerebral infarction and dyskinesia; Alginic Sodium Diester injection for ischemic heart, cerebrovascular, and high lipoprotein blood diseases; Bumetanide injection to treat edema diseases; and Candesartan for hypertension. In addition, the company provides Roxithromycin dispersible tablets for pharyngitis and tonsillitis; Cefaclor dispersible tablets for tympanitis, lower respiratory tract infection, urinary tract infections, and skin/skin tissue infection; Cefalexin capsules for acute tonsillitis; Andrographolide for sore throat caused by upper respiratory tract infection; Clarithromycin granules and capsules; and Naproxen Sodium and PseudophedrineHydrochlorida sustained release tablets. Further it offers Hepatocyte growth-promoting factor, Tiopronin, Compound Ammonium Glycyrrhetate S, and Omeparzole for the treatment of digestive diseases. Additionally, the company provides Vitamin B6 injection; Granisetron Hydrochloride injection to treat nausea and vomiting caused by radiotherapy and chemotherapy during the treatment of malignant tumors; Noni Enzyme, a food supplement; sanitizers; and masks. It offers its products through distributors, its network of sales offices, and sales representatives. The company is based in Haikou, the People's Republic of China.Ernexa Therapeutics NASDAQ:ERNA$6.15 -0.40 (-6.11%) Closing price 04:00 PM EasternExtended Trading$6.37 +0.22 (+3.51%) As of 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Eterna Therapeutics Inc., a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited. Eterna Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.Lisata Therapeutics NASDAQ:LSTA$3.56 +0.08 (+2.30%) Closing price 04:00 PM EasternExtended Trading$3.56 0.00 (0.00%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SpaceX Rings the Bell and Shatters Every Record Adobe Stock Just Got Cheaper—Is Wall Street Missing the Story? ERock IPO: A $1.3B Power Play Solution Boeing’s Unseen Rebound: Why the Headlines Are Wrong Why Oracle's 10% Drop May Be Telling the Wrong Story Spotify's "North Star" Outlook Was Music to Investors Ears DraftKings Hits the Jackpot With Super App Pivot Cracker Barrel Surges 23% as Earnings Beat Signals Turnaround Progress Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
